Press Releases

Pfizer Inc announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA® (Meningococcal Group B Vaccine) for review. TRUMENBA has been developed for the prevention of invasive meningococcal disease (IMD) caused...

Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program will generate additional data on symptom reduction, efficacy, safety, quality of...

73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour typesContinued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation,...

Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in adult and pediatric patients. Late-breaking Phase 2 data evaluates risankizumab, an anti-IL-23 monoclonal biologic antibody for...

Bayer announced that data from several studies across its oncology portfolio will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 3-7 in Chicago, Illinois (USA). The...

Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression Therapeutic Factor IX activity sustained at levels exceeding those considered sufficient to reduce the risk of joint bleeds and...

Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up. KEYNOTE-001 Findings Show Continued Benefit in Response...